v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Total revenues $ 33,736 $ 24,066
Operating expenses:    
Cost of revenue 0 (137)
Research and development (11,822) (21,522)
General and administrative (6,860) (15,718)
Total operating expenses (18,682) (37,377)
Operating income (loss) 15,054 (13,311)
Other income (expense):    
Non-operating income (expense) (208) (264)
MiNK Therapeutics, Inc. equity method investment fair value adjustment (1,350) 0
Gain on Zydus asset sale 40,379 0
Interest expense, net (14,669) (12,795)
Net income (loss) 39,206 (26,370)
Dividends on Series A-1 convertible preferred stock (54) (54)
Less: net loss attributable to non-controlling interest (20) (1,104)
Net income (loss) attributable to Agenus Inc. common stockholders $ 39,172 $ (25,320)
Per common share data:    
Basic net income (loss) attributable to Agenus Inc. comm stockholders $ 1.03 $ (1.03)
Diluted net income (loss) attributable to Agenus Inc. comm stockholders $ 1.02 $ (1.03)
Weighted average number of Agenus Inc. common shares outstanding:    
Basic 37,941 24,469
Diluted 38,285 24,469
Other comprehensive income (loss):    
Foreign currency translation gain (loss) $ 2 $ (70)
Other comprehensive income (loss) 2 (70)
Comprehensive income (loss) 39,174 (25,390)
Pre-Commercial Product Revenue [Member]    
Revenue:    
Total revenues 4,591 0
Service Revenue [Member]    
Revenue:    
Total revenues 0 510
Non-Cash Royalty Revenue Related to the Sale of Future Royalties [Member]    
Revenue:    
Total revenues $ 29,145 $ 23,556